An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain

Oscar Corli, Mauro Montanari, Silvia Deandrea, Maria Teresa Greco, Walter Villani, Giovanni Apolone

Research output: Contribution to journalArticle

Abstract

Objective. This analysis, carried out in the context of a wider observational prospective study, tried to explore whether four World Health Organization/step-III opioids (morphine, oxycodone, fentanyl, and buprenorphine) had different effectiveness when using several different outcomes and endpoints. Design. Cross-sectional and longitudinal design. Setting. Oncologic, palliative, and pain centers in Italy. Patients. Two hundred fifty-eight cancer patients monitored over a 3-week follow-up program. Intervention. Not applicable. Outcome Measures. The analgesic efficacy was assessed using effectiveness endpoints, such as pain intensity, pain intensity difference (PID), proportion of nonresponders (NR) and full-responders (FR) subjects, percentage of switches and dose escalation. Results. Mean values of PID led to differences among opioids ranging from 10% to 30%. FR (PID≥30%) were more frequent in buprenorphine-fentanyl-oxycodone groups than in morphine; NR (PID≤0%) were variable. The percentage of switches resulted three times more frequent when using morphine than buprenorphine (24.4% vs 8.6%). An increase of dose ≥5% a day was observed in 33.3% of fentanyl patients vs 15% of buprenorphine. As a whole, opioids show some different behaviors on the basis of the considered endpoints. Conclusions. The observed results, even if the small sample size and the nature itself of the study do not allow a definitive evaluation of the effectiveness of the drugs, underline a degree of variability among opioids and address toward a correct planning of a comparative randomized clinical trial that is now underway in Italy. For this reason, a confirmative effectiveness randomized controlled trial is required. Wiley Periodicals, Inc.

Original languageEnglish
Pages (from-to)897-907
Number of pages11
JournalPain Medicine (United States)
Volume13
Issue number7
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Buprenorphine
Opioid Analgesics
Fentanyl
Morphine
Oxycodone
Pain
Italy
Randomized Controlled Trials
Pain Clinics
Drug Evaluation
Sample Size
Observational Studies
Analgesics
Outcome Assessment (Health Care)
Prospective Studies
Cancer Pain
Neoplasms

Keywords

  • Cancer Pain
  • Opioids Dose Escalation
  • Opioids Effectiveness
  • Opioids Switch

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain. / Corli, Oscar; Montanari, Mauro; Deandrea, Silvia; Greco, Maria Teresa; Villani, Walter; Apolone, Giovanni.

In: Pain Medicine (United States), Vol. 13, No. 7, 07.2012, p. 897-907.

Research output: Contribution to journalArticle

Corli, Oscar ; Montanari, Mauro ; Deandrea, Silvia ; Greco, Maria Teresa ; Villani, Walter ; Apolone, Giovanni. / An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain. In: Pain Medicine (United States). 2012 ; Vol. 13, No. 7. pp. 897-907.
@article{b75a6b586ca9496cab3bc36c7f500624,
title = "An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain",
abstract = "Objective. This analysis, carried out in the context of a wider observational prospective study, tried to explore whether four World Health Organization/step-III opioids (morphine, oxycodone, fentanyl, and buprenorphine) had different effectiveness when using several different outcomes and endpoints. Design. Cross-sectional and longitudinal design. Setting. Oncologic, palliative, and pain centers in Italy. Patients. Two hundred fifty-eight cancer patients monitored over a 3-week follow-up program. Intervention. Not applicable. Outcome Measures. The analgesic efficacy was assessed using effectiveness endpoints, such as pain intensity, pain intensity difference (PID), proportion of nonresponders (NR) and full-responders (FR) subjects, percentage of switches and dose escalation. Results. Mean values of PID led to differences among opioids ranging from 10{\%} to 30{\%}. FR (PID≥30{\%}) were more frequent in buprenorphine-fentanyl-oxycodone groups than in morphine; NR (PID≤0{\%}) were variable. The percentage of switches resulted three times more frequent when using morphine than buprenorphine (24.4{\%} vs 8.6{\%}). An increase of dose ≥5{\%} a day was observed in 33.3{\%} of fentanyl patients vs 15{\%} of buprenorphine. As a whole, opioids show some different behaviors on the basis of the considered endpoints. Conclusions. The observed results, even if the small sample size and the nature itself of the study do not allow a definitive evaluation of the effectiveness of the drugs, underline a degree of variability among opioids and address toward a correct planning of a comparative randomized clinical trial that is now underway in Italy. For this reason, a confirmative effectiveness randomized controlled trial is required. Wiley Periodicals, Inc.",
keywords = "Cancer Pain, Opioids Dose Escalation, Opioids Effectiveness, Opioids Switch",
author = "Oscar Corli and Mauro Montanari and Silvia Deandrea and Greco, {Maria Teresa} and Walter Villani and Giovanni Apolone",
year = "2012",
month = "7",
doi = "10.1111/j.1526-4637.2012.01408.x",
language = "English",
volume = "13",
pages = "897--907",
journal = "Pain Medicine",
issn = "1526-2375",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - An exploratory analysis on the effectiveness of four strong opioids in patients with cancer pain

AU - Corli, Oscar

AU - Montanari, Mauro

AU - Deandrea, Silvia

AU - Greco, Maria Teresa

AU - Villani, Walter

AU - Apolone, Giovanni

PY - 2012/7

Y1 - 2012/7

N2 - Objective. This analysis, carried out in the context of a wider observational prospective study, tried to explore whether four World Health Organization/step-III opioids (morphine, oxycodone, fentanyl, and buprenorphine) had different effectiveness when using several different outcomes and endpoints. Design. Cross-sectional and longitudinal design. Setting. Oncologic, palliative, and pain centers in Italy. Patients. Two hundred fifty-eight cancer patients monitored over a 3-week follow-up program. Intervention. Not applicable. Outcome Measures. The analgesic efficacy was assessed using effectiveness endpoints, such as pain intensity, pain intensity difference (PID), proportion of nonresponders (NR) and full-responders (FR) subjects, percentage of switches and dose escalation. Results. Mean values of PID led to differences among opioids ranging from 10% to 30%. FR (PID≥30%) were more frequent in buprenorphine-fentanyl-oxycodone groups than in morphine; NR (PID≤0%) were variable. The percentage of switches resulted three times more frequent when using morphine than buprenorphine (24.4% vs 8.6%). An increase of dose ≥5% a day was observed in 33.3% of fentanyl patients vs 15% of buprenorphine. As a whole, opioids show some different behaviors on the basis of the considered endpoints. Conclusions. The observed results, even if the small sample size and the nature itself of the study do not allow a definitive evaluation of the effectiveness of the drugs, underline a degree of variability among opioids and address toward a correct planning of a comparative randomized clinical trial that is now underway in Italy. For this reason, a confirmative effectiveness randomized controlled trial is required. Wiley Periodicals, Inc.

AB - Objective. This analysis, carried out in the context of a wider observational prospective study, tried to explore whether four World Health Organization/step-III opioids (morphine, oxycodone, fentanyl, and buprenorphine) had different effectiveness when using several different outcomes and endpoints. Design. Cross-sectional and longitudinal design. Setting. Oncologic, palliative, and pain centers in Italy. Patients. Two hundred fifty-eight cancer patients monitored over a 3-week follow-up program. Intervention. Not applicable. Outcome Measures. The analgesic efficacy was assessed using effectiveness endpoints, such as pain intensity, pain intensity difference (PID), proportion of nonresponders (NR) and full-responders (FR) subjects, percentage of switches and dose escalation. Results. Mean values of PID led to differences among opioids ranging from 10% to 30%. FR (PID≥30%) were more frequent in buprenorphine-fentanyl-oxycodone groups than in morphine; NR (PID≤0%) were variable. The percentage of switches resulted three times more frequent when using morphine than buprenorphine (24.4% vs 8.6%). An increase of dose ≥5% a day was observed in 33.3% of fentanyl patients vs 15% of buprenorphine. As a whole, opioids show some different behaviors on the basis of the considered endpoints. Conclusions. The observed results, even if the small sample size and the nature itself of the study do not allow a definitive evaluation of the effectiveness of the drugs, underline a degree of variability among opioids and address toward a correct planning of a comparative randomized clinical trial that is now underway in Italy. For this reason, a confirmative effectiveness randomized controlled trial is required. Wiley Periodicals, Inc.

KW - Cancer Pain

KW - Opioids Dose Escalation

KW - Opioids Effectiveness

KW - Opioids Switch

UR - http://www.scopus.com/inward/record.url?scp=84863883152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863883152&partnerID=8YFLogxK

U2 - 10.1111/j.1526-4637.2012.01408.x

DO - 10.1111/j.1526-4637.2012.01408.x

M3 - Article

C2 - 22680789

AN - SCOPUS:84863883152

VL - 13

SP - 897

EP - 907

JO - Pain Medicine

JF - Pain Medicine

SN - 1526-2375

IS - 7

ER -